KR20140130664A - 외피 바이러스에 의해 야기되는 질병의 치료를 위한 시알로어드히신의 억제제들 - Google Patents

외피 바이러스에 의해 야기되는 질병의 치료를 위한 시알로어드히신의 억제제들 Download PDF

Info

Publication number
KR20140130664A
KR20140130664A KR20147019234A KR20147019234A KR20140130664A KR 20140130664 A KR20140130664 A KR 20140130664A KR 20147019234 A KR20147019234 A KR 20147019234A KR 20147019234 A KR20147019234 A KR 20147019234A KR 20140130664 A KR20140130664 A KR 20140130664A
Authority
KR
South Korea
Prior art keywords
hiv
virus
antigen
cells
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20147019234A
Other languages
English (en)
Korean (ko)
Inventor
누리아 이즈퀴에르도 유세로스
한스-게오르그 크라우슬리히
마이에르 로리자테
하비에르 마르티네즈 피카도
Original Assignee
라보라토리오스 델 드라. 에스테브.에스.에이.
인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠(아이크레아)
푼다시오 프리바다 인스티튜트 데 레세르사 데 라 시다 - 카이사
루프레히트-칼스-유니페어지테트 하이델베르크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라보라토리오스 델 드라. 에스테브.에스.에이., 인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠(아이크레아), 푼다시오 프리바다 인스티튜트 데 레세르사 데 라 시다 - 카이사, 루프레히트-칼스-유니페어지테트 하이델베르크 filed Critical 라보라토리오스 델 드라. 에스테브.에스.에이.
Publication of KR20140130664A publication Critical patent/KR20140130664A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR20147019234A 2011-12-22 2012-12-17 외피 바이러스에 의해 야기되는 질병의 치료를 위한 시알로어드히신의 억제제들 Withdrawn KR20140130664A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161579242P 2011-12-22 2011-12-22
EP11382392.6 2011-12-22
US61/579,242 2011-12-22
EP11382392.6A EP2606897A1 (en) 2011-12-22 2011-12-22 Methods and compositions for the treatment of diseases caused by enveloped viruses
PCT/EP2012/075831 WO2013092509A1 (en) 2011-12-22 2012-12-17 Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses

Publications (1)

Publication Number Publication Date
KR20140130664A true KR20140130664A (ko) 2014-11-11

Family

ID=45445920

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147019234A Withdrawn KR20140130664A (ko) 2011-12-22 2012-12-17 외피 바이러스에 의해 야기되는 질병의 치료를 위한 시알로어드히신의 억제제들

Country Status (14)

Country Link
US (1) US9789130B2 (enExample)
EP (2) EP2606897A1 (enExample)
JP (1) JP6143781B2 (enExample)
KR (1) KR20140130664A (enExample)
CN (1) CN104168903B (enExample)
AU (1) AU2012357968B2 (enExample)
BR (1) BR112014015112A8 (enExample)
CA (1) CA2858499A1 (enExample)
HK (1) HK1202820A1 (enExample)
IL (1) IL233207A0 (enExample)
MX (1) MX2014007605A (enExample)
RU (1) RU2014130022A (enExample)
WO (1) WO2013092509A1 (enExample)
ZA (1) ZA201403861B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023128551A1 (ko) * 2021-12-27 2023-07-06 주식회사 진켐 시알릴락토스를 이용한 혈뇌장벽 투과용 약물 전달체

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004695B2 (en) 2014-04-16 2018-06-26 Trustees Of Boston University GM3 functionalized nanoparticles
CN104587491A (zh) * 2014-12-30 2015-05-06 天津大学 SAMHD1-pLNCX2制备抗肿瘤药物的用途
AU2017261840A1 (en) * 2016-05-06 2018-11-22 WRS Nutraceuticals Pty Ltd Agent delivery system
CN109906381B (zh) * 2016-08-31 2023-03-31 新加坡科技研究局 鉴别、靶向以及分离人树突细胞(dc)前体“前dc”的方法及其用途
CN108165559B (zh) * 2017-11-29 2021-06-18 昆明理工大学 一种c2h2型转录因子基因及其应用
US20250302865A1 (en) * 2022-03-16 2025-10-02 Pharmalectin, Inc. Lectin-binding carbohydrates for treating viral infections
KR20240102304A (ko) * 2022-12-26 2024-07-03 주식회사 진켐 신규한 젬시타빈 결합체 및 이의 용도
CN117886891B (zh) * 2024-03-15 2024-06-07 黑龙江八一农垦大学 靶向巨噬细胞cd169受体的多肽及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
US3888975A (en) 1972-12-27 1975-06-10 Alza Corp Erodible intrauterine device
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (enExample) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
NL7807532A (nl) 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
FR2433949A1 (fr) 1978-08-25 1980-03-21 Commissariat Energie Atomique Substrat hydrophobe apte a liberer une substance chimique
US4954487A (en) 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
NL8000173A (nl) 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4360013A (en) 1980-04-21 1982-11-23 Minnesota Mining And Manufacturing Company Polymeric acid contraceptive devices
IT1131833B (it) 1980-06-20 1986-06-25 Crinos Industria Farmaco Eccipienti per sostanze spermicide
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4368186A (en) 1981-05-07 1983-01-11 Syntex (U.S.A.) Inc. Methods and compositions for intravaginal contraception
US4415585A (en) 1982-03-11 1983-11-15 University Of Illinois Foundation Contraceptive method
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5248700A (en) 1982-05-14 1993-09-28 Akzo Nv Active agent containing solid structures for prolonged release of active agents
US4961931A (en) 1982-07-29 1990-10-09 Alza Corporation Method for the management of hyperplasia
US4499154A (en) 1982-09-03 1985-02-12 Howard L. Podell Dipped rubber article
US4551148A (en) 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5624824A (en) 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5208031A (en) 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
DE4015543A1 (de) 1990-05-15 1991-11-21 Bayer Ag Spermicides beschichtungsmittel
DE69119312T2 (de) 1990-07-18 1997-01-16 Abbott Lab Analyt-Austauschreagenz zur Verwendung in spezifischen Bindungstests, -vorrichtungen und -sätzen
US5143731A (en) 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
FR2666587B1 (fr) 1990-09-10 1993-06-25 Dow Corning Sa Compositions de lubrifiant et leur utilisation.
GB9021061D0 (en) 1990-09-27 1990-11-07 Unilever Plc Encapsulating method and products containing encapsulated material
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
US5698411A (en) 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5759781A (en) 1995-12-22 1998-06-02 Yale University Multiparametric fluorescence in situ hybridization
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5876935A (en) 1997-01-08 1999-03-02 Dade Behring Inc. Luminescent specific binding assay
SE9700383D0 (sv) 1997-02-04 1997-02-04 Pharmacia Biotech Ab An adsorption/separation method and a medium for adsorption/separation
CA2340118C (en) 1998-08-12 2009-01-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
US6809186B1 (en) 1999-01-22 2004-10-26 Martek Biosciences Corporation Simple method for labeled conjugate production
EP1168924A4 (en) 1999-03-31 2002-09-04 Univ Pittsburgh DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL
US20030092091A1 (en) * 2000-03-07 2003-05-15 Abrahamson Julie A. Sialoadhesin factor-2 antibodies
MXPA03005373A (es) 2000-12-13 2004-03-26 Inmunex Corp Metodo para generar lineas celulares dentriticas inmortales.
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
EP1572242B1 (en) 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
WO2005051315A2 (en) 2003-11-24 2005-06-09 The Regents Of The University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
CN101484182B (zh) 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
JP5231231B2 (ja) 2005-10-19 2013-07-10 アイビーシー・ファーマシューティカルズ・インコーポレーテッド 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用
EP2060257A1 (en) * 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
JP5641598B2 (ja) * 2009-09-29 2014-12-17 雪印メグミルク株式会社 シアリルラクトース素材の分離方法
JP5788653B2 (ja) * 2010-09-10 2015-10-07 靖人 江原 糖鎖修飾ヌクレオチド及びその使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023128551A1 (ko) * 2021-12-27 2023-07-06 주식회사 진켐 시알릴락토스를 이용한 혈뇌장벽 투과용 약물 전달체

Also Published As

Publication number Publication date
AU2012357968B2 (en) 2017-10-05
MX2014007605A (es) 2015-07-06
US20140370052A1 (en) 2014-12-18
RU2014130022A (ru) 2016-02-10
CA2858499A1 (en) 2013-06-27
EP2606897A1 (en) 2013-06-26
US9789130B2 (en) 2017-10-17
EP2793904A1 (en) 2014-10-29
IL233207A0 (en) 2014-07-31
JP6143781B2 (ja) 2017-06-07
JP2015500854A (ja) 2015-01-08
CN104168903B (zh) 2017-05-31
HK1202820A1 (en) 2015-10-09
CN104168903A (zh) 2014-11-26
BR112014015112A2 (pt) 2017-06-13
WO2013092509A1 (en) 2013-06-27
NZ627650A (en) 2016-01-29
BR112014015112A8 (pt) 2017-06-13
AU2012357968A1 (en) 2014-08-14
ZA201403861B (en) 2015-09-30

Similar Documents

Publication Publication Date Title
US9789130B2 (en) Method for blocking HIV entry into dendritic cells by inhibiting sialoadhesin-sialyllactose binding interactions with gangliosides
RU2746383C2 (ru) Способы и композиции для лечения персистирующих инфекций
Tsunetsugu-Yokota et al. Yeast-derived human immunodeficiency virus type 1 p55 gag virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8+ T cells by cross-presentation of DCs
Dumais et al. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge
EP3122380A1 (en) Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
KR20090060410A (ko) 인간 내인성 레트로바이러스 폴리펩타이드 조성물 및 이들의 사용 방법
JP2010539901A (ja) 長鎖散在反復配列ポリペプチド組成物およびその使用方法
Kijewski et al. Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated
NZ627650B2 (en) Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses
Diou et al. Dendritic cells derived from hemozoin-loaded monocytes display a partial maturation phenotype that promotes HIV-1 trans-infection of CD4+ T cells and virus replication
US20090136546A1 (en) Immunomodulating compositions and uses therefor
EP1391729A1 (en) Antitumor antigen against htlv-1 tumor or antigen epitope thereof
Valencia Hernandez Inducing immunity to liver stage malaria through endogenous tissue resident memory cells
Yoshizawa et al. Studies on the generation and maintenance of mucosal cytotoxic T lymphocytes against human immunodeficiency virus type 1 Gag in mice
Inizan Human Immunodeficiency Virus Type I subverts T cell extracellular matrix to shelter cell-associated infectivity in a viral biofilm
J. Kimura et al. Application of innate immune molecules for a new class of drugs: infection, inflammation and beyond
Smed Sörensen On the role of dendritic cells in HIV-1 infection
KR20070019635A (ko) 면역원성 ｈｉｖ 조성물 및 이와 관련된 방법
Berzi et al. EVALUATION OF ANTI-INFECTIVE ACTIVITY OF GLYCOMIMETIC DC-SIGN LIGANDS
Rane Impact of Th1 CD4 TFH skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques
Hebbandi Nanjundappa HIV-1 Glycoprotein 120-Specific Exosome-Targeted CD8+ T Cell Vaccine
MXPA01010784A (en) Hiv immunogenic compositions and methods

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140710

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171218

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20190114

WITB Written withdrawal of application